Supreme Court agrees to take up generic drug access issue while Vitter seeks legislative solution

WASHINGTON – The U.S. Supreme Court Monday agreed to take a case on whether brand-name drug manufacturers should be allowed to pay generic drug manufacturers to  delay production of cheaper versions of medicines. The Federal Trade Commission has labeled this process as “pay for delay.”

via Supreme Court agrees to take up generic drug access issue while Vitter seeks legislative solution | NOLA.com.